Geminin (GMNN)

Geminin is a critical nuclear protein that regulates the eukaryotic cell cycle by preventing DNA re-replication. It performs this function by binding to and inhibiting Cdt1, an essential factor for the assembly of the pre-replication complex (pre-RC) at origins of replication. Geminin levels are tightly regulated; the protein is absent during the G1 phase to allow replication licensing but accumulates during S, G2, and M phases to block further licensing, ensuring genomic integrity. In addition to its role in DNA replication, Geminin is involved in cell fate decisions, particularly in neural development, where it interacts with the SWI/SNF chromatin-remodeling complex. In the context of oncology, Geminin is frequently overexpressed in various malignancies, including breast, colon, and lung cancers, where it often serves as a marker of high proliferation and poor prognosis. Because cancer cells often have compromised cell cycle checkpoints, targeting the Geminin-Cdt1 axis is an attractive therapeutic strategy to induce catastrophic DNA re-replication and apoptosis specifically in tumor cells. While direct small-molecule inhibitors are still largely in the experimental stage, Geminin remains a significant target for diagnostic applications and the development of novel anti-proliferative therapies.

Other names

DNA replication inhibitorGeminin coiled-coil domain-containing protein 1GMNN

Geminin functions by binding to and sequestering Cdt1, a key component of the pre-replication complex, thereby preventing the loading of the Minichromosome Maintenance (MCM) complex onto DNA origins during the S, G2, and M phases of the cell cycle. This inhibition ensures that DNA replication occurs only once per cell cycle. Therapeutic strategies often focus on modulating Geminin levels or its interaction with Cdt1 to induce DNA re-replication and subsequent apoptosis in cancer cells, or using it as a diagnostic marker for proliferative activity.